Compound class:
Synthetic organic
Comment: LPC-233 is an orally bioavailable preclinical antibacterial compound that inhibits bacterial UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) and has potent activity against a wide range of Gram-negative bacteria in vitro [5].
|
|
References |
1. Erwin AL. (2016)
Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC. Cold Spring Harb Perspect Med, 6 (7). [PMID:27235477] |
2. Niu Z, Lei P, Wang Y, Wang J, Yang J, Zhang J. (2023)
Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives. Eur J Med Chem, 253: 115326. [PMID:37023679] |
3. Raetz CR. (1993)
Bacterial endotoxins: extraordinary lipids that activate eucaryotic signal transduction. J Bacteriol, 175 (18): 5745-53. [PMID:8376321] |
4. Raetz CR, Guan Z, Ingram BO, Six DA, Song F, Wang X, Zhao J. (2009)
Discovery of new biosynthetic pathways: the lipid A story. J Lipid Res, 50 Suppl (Suppl): S103-8. [PMID:18974037] |
5. Zhao J, Cochrane CS, Najeeb J, Gooden D, Sciandra C, Fan P, Lemaitre N, Newns K, Nicholas RA, Guan Z et al.. (2023)
Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens. Sci Transl Med, 15 (708): eadf5668. [PMID:37556556] |